What are ADC's

ADC 101
ADC Drug Map
Recommended Reading

ADC Review
is made possible by:

ADC Drug Map

CLICK ON THE HUMAN TO SEE WHICH ADCs ARE BEING DEVELOPED FOR THAT SPECIFIC ORGAN

Filter by Cancer

Bladder cancer
Myeloma
Leukemia
Breast cancer
Colon cancer
Esophageal cancer
Kidney cancer
Colorectal cancer
Liver cancer
Lung cancer
Hodgkin's disease
Lymphoma
Mesenteric Lymphadenitis
Ovarian cancer
Pancreatic cancer
Prostate cancer
Rectal cancer
Skin cancer
Small Intestine cancer
Spleen cancer
Stomach cancer
Uterine cancer
White blood cells

ADC

Clear Filter

AB-3A4 ADCAlethia Biotherapeutics
ABBV-176 (ABV176)Abbvie
AbGn-107 (Ab1-18Hr1)AbGenomics BV | Taiwan Branch
AbGn-108AbGenomics International
AbGn-110AbGenomics International
ADCT-502ADC Terapeutics
ADCT-601ADC Therapeutics
ADCT-602 (hLL2-cys-PBD)ADC Therapeutics
ADCT-701ADC Therapeutics
AGS-16C3F (AGS 16C3F / AGS-16M8F)Agensys/Astellas
AGS-16M8F (AGS 16C3F / AGS-16C3F)Agensys/Astellas
AGS62P1Agensys/Astellas
ALT-P73SBIO | Alteogen
AMG 224Amgen
AMG-595Amgen
AMG172Amgen, Inc
Anetumab Ravtansine (BAY 94-9343)Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc.
Anti-ADAM9 ADC (Anti-ADAM9-sulfoSPDB-DM4)Macrogenics and ImmunoGen
Anti-ADAM9 ADC (Anti-ADAM9(C442)-DGN549)Macrogenics and ImmunoGen
Anti-CD19 ATAC (anti-CD19 ADC)Heidelberg Pharma/Wilex
Anti-CD22-NMS249Genentech and Nerviano Medical Sciences
Anti-CD70-ADC (CD70-ADC)Ambrx
Anti-cMET ADC (CBT-161)Sorrento Therapeutics
Anti-endosialin-MC-VC-PABC-MMAEGenzyme
Anti-ETBR (RG-7636)Genentech/Roche
anti-HER-3 ADCMediaPharma
anti-TEM-1 Antibody-Drug Conjugate (TEM-1-ADC).MediaPharma S.r.l.
Anti-TM4SF1 ADCThe Center for Vascular Biology Research and the Departments of Angiex; Pfizer; Pathology, Beth Israel Deaconess Medical Center (BIDMC); Harvard Medical School, Boston, Massachusetts
Aprutumab ixadotin (BAY 1187982)Bayer HealthCare Pharmaceuticals
AR-001 | YBL-001Y-Biologics
ARX517-PSMA-ADCAmbrx
ARX788 HER2 ADCZhejiang Medicine Co. | Ambrx
ASG-22CEAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
ASN-004 (ASN 004)Asana Biosciences
AVID100Formation Biologics
AVID300 | AVID 300Formation Biologics
Azintuxizumab vedotin (ABBV-838)AbbVie
Azonafide-ADCOncolinx
BA3011 | CAB-Axl-ADC (CAB-anti-Axl-ADC)BioAtla
BA3021 | Anti-ROR2 ADC | CAB-ROR2-ADCBioAtla
BAY79-4620Bayer HealthCare
Belantamab mafodotin
BIIB-015 | BIIB015Biogen
Bivatuzumab mertansine | Anti-CD44v6-DM1 | BIWI-1Boehringer Ingelheim | ImmunoGen
Brentuximab vedotin (SGN35 / Adcetris®)Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan)
Bstrongximab-ADCCureMeta
BT1718 (BT 1718)Bicycle Therapeutics
c-MET ADCConcortis Biotherapeutics
Camidanlumab tesirine (ADCT-301 | HuMax-TAC-ADC)Genmab | ADC Therapeutics
Cantuzumab mertansine | huC242-DM1 | SB-408075GlaxoSmithKline (GSK) / ImmunoGen
Cantuzumab Ravtansine (IMGN-242)ImmunoGen
CD184-Dasatinib (CD184-Dasatinib-ADC)Ambrx
CD184-FK506Ambrx
CD22-4APCatalent Pharma Solutions and Triphase Accelerator Corporation
CD70-glucocorticoid ADCMerck & Co and Ambrx
CDX-014Celldex Therapeutics
Cirmtuzumab Vedotin | UC-961ADC3Thomas Kipps, University of California, San Diego
Clivatuzumab TetraxetanImmunmedics
CMB-401 | hCTMO1-calicheamicin | CDP-671Pfizer (Wyeth Pharmaceuticals); Celltech
Cofetuzumab pelidotin (PF-06647020)Pfizer / Stemcentrx (AbbVie)
Coltuximab Ravtansine (SAR 3419)ImmunoGen (previously also Sanofi)
CX-2009Cytomx
Cymac-001 (anti-CD163-dexamethasone ADC)Affinicon
D3-GPC2-PBD (anti-GPC2 ADC)Children's Hospital of Philadelphia (CHOP
DEDN6526A (RG-7636 / RG7636)Genentech/Roche
Denintuzumab mafodotin (SGN-CD19A / SGN-19A)Seattle Genetics
Depatuxizumab Mafodotin | ABT-414AbbVie (prior sponsor, Abbott)
DMOT4039A (DMOT-4039A / RG7600 / RG 7600)Genentech Inc. (South San Francisco, CA, USA) / Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
DS-1062 (TROP2 ADC)Daiichi Sankyo
DS-7300 (B7-H3 ADC)Daiichi Sankyo Company
DSTA4637S (Anti-S. aureus TAC; RG7861)Genentech
EC1169Endocyte
EC2629Endocyte
EDC1 (DYS-ADC)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
EDC9 (EDC-CD20)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
EDO-772P/B776Mundipharma EDO GmbH
EDO-B278Mundipharma EDO GmbH
Enapotamab vedotin | HuMax-AXL-ADC | AXL-107-MMAEGenmab
Enfortumab Vedotin | ASG-22ME | ASG-22MSEAstellas Pharma (Agensys) / Seattle Genetics
EP-400Esperance Pharmaceuticals
Epratuzumab–SN-38Immunomedics
EV20/MMAFMediapharma
Gemtuzumab ozogamicin (Mylotarg®)Pfizer (Wyeth)
Glembatumumab vedotin (CDX-011)Celldex Therapeutics, Inc.
GM103GamaMabs
GSK2857916 (J6M0-mcMMAF)GSK
HDP-101 (Anti-CD269-ADC; Anti-CD269-amanitin-ADC)Heidelberg Pharma
Hertuzumab VedotinRongchang Pharmaceuticals / MabPlex (Yantai, China).
HKT288 (CDH6-ADC)Novartis and ImmunoGen
HTI-1511Halozyme
HuMAB-5B1-ATACWilex/Heidelberg Pharma in collaboration with MabVax
IGN523Igenica Biotherapeutics
IGN786Igenica Biotherapeutics
Iladatuzumab vedotin (DCDS0780A; RO7032005)F. Hoffmann-La Roche
IMAB027-vcMMAEGanymed Pharmaceuticals | Astellas
IMAB362-vcMMAEAstellas (Ganymed Pharmaceuticals)
IMB-201ImmunoBiochem
IMB-202ImmunoBiochem
IMGN 289ImmungoGen
IMGN 779 | IMGN779ImmunoGen, Inc.
IMGN-242ImmunoGen
IMGN-388ImmunoGen
IMGN-633 (AVE9633)ImmunoGen
IMGN632 | IMGN 632ImmunoGen
IMMU-140 (anti-HLA-DR-SN-38 ADC)Immunomedics
Indatuximab Ravtansine | BT-062ImmunoGen | BioTest
Industuzumab Vedotin (MLN-0264 | TAK-264)Takeda / Millennium Pharmaceuticals
Inotuzumab ozogamicin (CMC-544) | BESPONSA®Pfizer (Wyeth Pharmaceuticals)
KTN0125Kolltan Pharmaceuticals
KTN0182AKolltan Pharmaceuticals
Labetuzumab govitecan (IMMU-130)Immunomedics
Ladiratuzumab vedotin (SGN-LIV1A; Anti-LIV-1 ADC)Seattle Genetics
Laprituximab emtansine (IMGN-289, IMGN289)ImmunoGen
LCB14-0110 (Herceptin-LC-LBG-MMAF)Legochem Biosciences and Fosun Pharma
LCB14-15nmLegoChem Biosciences and Takeda
LCB14-15xxLegoChem Biosciences and Y-Biologics
LCB14-15xx (NNV019)LegoChem Biosciences and Nordic Nanovector
LCB14-17nnLegoChem Biosciences and Gree Cross
LCB14-19nmLegoChem Biosiences and Samsung Medical Center
LCB14-2nmLegoChem Biosciences and Seasun Biomaterials
Lifastuzumab Vedotin (RG-7599 / DNIB0600A)Roche, F. Hoffmann-La Roche / Genentech
Loncastuximab tesirine (ADCT-402)ADC Therapeutics SARL
LOP628 (LOP-628)Novartis Pharmaceuticals
Lorvotuzumab mertansine (IMGN-901)ImmunoGen
Losatuxizumab vedotin (ABBV-221)AbbVie
Lupartumab amadotin (BAY 1129980)Bayer
LY3076226Eli Lilly and Company
MDX-060 / iratumumabMedarex/Bristol-Myers Squibb
MDX-1203 | BMS936561Medarex | Bristol-Myers Squibb
MEDI-547MedImmune
MEDI3726 | ADCT-401ADC Therapeutics in collaboration with MedImmune/AstraZeneca
MEDI4276 (MEDI 4276)Medimmune / AstraZeneca
MEN1309 | OBT076Co-developed by Menarini Ricerche and Oxford BioTherapeutics
MGC018; Anti-B7-H3 ADCMacroGenics
MI130004PharmaMar
Milatuzumab doxorubicin (hLL1-DOX | IMMU-110)Immunomedics
Mirvetuximab Soravtansine (IMGN-853)ImmunoGen (Cambridge MA USA)
MLN-2704 | MLN2704Millennium/ Takeda
MM-302Merrimack Pharmaceuticals, Inc.
MORAb-202Morphotek®, a subsidiary of Eisai
Naratuximab emtansine (IMGN529 | K7153A) | Debio 1562 )ImmunoGen | Debiopharm Internaltional
NBE-002NBE Therapeutics GmbH
NC-6201 (ADCM-E7974)NanoCarrier Co.,Ltd (Japan) and Eisai
NV101 (Doxorubicin-anti-CD99)NanoValent Pharmaceuticals
NV102 (Doxorubicin-anti-CD19)NanoValent Pharmaceuticals
NV103 (Irinotecan-anti-CD99)NanoValent Pharmaceuticals
OBI-999 | Anti-Globo H ADCOBI Pharma
OMTX503 (Anti-MTX3:Nigrin Immunoconjugate)Oncomatryx Biopharma
OMTX705 (Anti-MTX5:Cytolysin ADC)Oncomatryx Biopharma
OXS-1550 (DT2219ARL)GT Biopharma. Previously known as Oxis Biotech (Georgetown Translational Pharmaceuticals)
PCA062 (PCA-062)ImmunogGen and Novartis
PEN-221Tarveda Therapeutics
PF 06263507 (A1-mcMMAF | Anti-5T4 monoclonal antibody | PF-06263507 | PF06263507)Oxford BioMedica; Pfizer (Wyeth)
PF-06647263 (anti-EFNA4-ADC)Pfizer
PF-06650808 (Anti-NOTCH3 ADC)Pfizer (Wyeth)
PF-06664178 | PF06664178 | PF 06664178Pfizer (Wyeth)
PF-06688992 | PF06688992Memorial Sloan-Kettering Cancer Center; Pfizer
PF-06804103 (Anti-NG-HER2 ADC)Pfizer
Pinatuzumab vedotin (RG-7593 / DCDT2980S / DCDT-2989S)Genentech / Roche, F. Hoffmann-La Roche (Roche)
Polatuzumab vedotin (RG-7596 / DCDS4501A / DCDS-4501A)Genentech / Roche, F. Hoffmann-La Roche
PSMA-ADCProgenics Pharmaceuticals, Inc. (Tarrytown NY USA)
Q5-Drug ConjugateAlteogen
RC-48 (RC 48-ADC)Yantai Rongchang Biological Engineering (RemeGen)
REGN2878-DM1 (Anti-PRLR-ADC)Regeneron
RG-7598 (DFRF 4539A / RG7598 / RG 7598)Genentech/Roche
RG-7841 (Anti-Ly6E / DLYE5953A)Genentech/Roche (in collaboration with Seattle Genetic)
RG7986Genentech/Roche
RM-1929Aspyrian Therapeutics, Inc.
Rovalpituzumab tesirine (Rova-T | SC0001)Stemcentrx (now part of AbbVie)
Sacituzumab govitecan (IMMU-132 / hRS7-SN38)Immunomedics
Samrotamab Vedotin | ABBV-085 | PR-1498487-MMAEAbbVie, Inc.
SAR 566658 (SAR566658)Sanofi; ImmunoGen
SAR408701 | SAR 408701Sanofi | ImmunoGen
SAR428926ImmunoGen; Sanofi
Satoreotide tetraxetan
SC-006AbbVie | Stemcentrx
SC16LD6.5Stem CentRx
SGN CD70 A | SGN-CD70A (superseding SGN-75)Seattle Genetics
SGN-15 (BMS-182248, BR96-DOX)Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)
SGN-CD123A
SGN-CD19BSeattle Genetics
SGN-CD352aSeattle Genetics
Sirtratumab vedotin (ASG-15ME)Co-developed by Astellas/Agensys and Seattle Genetics
SNG-8023 ADCShenogen Pharma Group
Sofituzumab vedotin (Anti-MUC16 ADC / RG7458 / DMUC5754A)Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
ST1Siamab Therapeutics
STRO-001 (Anti-CD74-ADC)Sutro Biopharma
SΤRO-002Sutro Biopharma
Tacatuzumab Tetraxetan
Telisotuzumab Vedotin (ABBV 399; ABBV399)AbbVie
TGM-001Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
TGM-002Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
TGM-003Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
TGM-004Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
TGM-005Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
Tisotumab Vedotin (HuMax®-TF-ADC)Co-developed by Genmab and Seattle Genetics
Trastuzumab deruxtecan (DS-8201, DS-8201a)Daiichi Sankyo Inc.
Trastuzumab duocarmazine (SYD985)Synthon Biopharmaceuticals
Trastuzumab-emtansine (T-DM1)Genentech/Roche
TRPH-222 (CD22-4AP)Triphase Accelerator Corporation, in collaboration with Celgene
U3-1402 (HER3 ADC)Daiichi Sankyo
Vadastuximab talirine (SGN-CD33A)Seattle Genetics
Vandortuzumab vedotin (RG7450; DSTP3086S)Genentech/ F. Hoffmann-La Roche (Roche)
VIS705Visterra
Vorsetuzumab mafodotin (SGN-75)Seattle genetics
VYNFINIT® | Vintafolide (EC145/MK 8109)Endocyte, Merck/MSD
XMT-1522Mersana Therapeutics in collaboration with Takeda
XMT-1536Mersana Therapeutics
ZV05-ADC (5T4-MMAF ADC)Zova Biotherapeutics (Zova Bio); Concortis Biotherapeutics (a subsidiary of Sorrento Therapeutics)
ZV203Concortis Biotherapeutics

How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?

10 October, 2018

In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month of his failure to disclose millions of dollars in payments from industry, I reached ou...

Eric Rosenthal Reports | A Personal Remembrance of Two Giants of Oncology: Jim and Jimmie Holland

03 April, 2018

James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the age of 92 on March 22. His wife, Jimmie C. Holland, MD, who was considered the founder...